Gas and bloating: abdominal distension, causes, tests and treatment

Gas, bloating and abdominal distension are related but different: gas passes through the digestive tract, bloating is a feeling of fullness or swelling, and distension is an increase in abdominal size. Symptoms may reflect food fermentation, swallowed air, constipation, sensitivity or another condition. Confidence is high that assessment should follow the symptom pattern and warning signs; a universal supplement or “gut reset” cure is not established. NIDDK definitions and causes.

Table of contents

• Evidence summary
• What are gas, bloating and abdominal distension?
• Why gas and bloating happen and when testing helps
• Cause-specific bloating treatment and symptom relief
• Food triggers, low-FODMAP diets and probiotic evidence
• Useful bloating outcomes, microbiome tests and formulation claims
• Bloating warning signs and treatment risks
• Medicines, fibre products and supplement interactions
• Children, restrictive eating and complex conditions
• Preparing a clinician-led bloating plan
• Animal and laboratory microbiome research limits
• Funding and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary

Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.

What are gas, bloating and abdominal distension?

Flatulence means passing wind, and some variation is normal. Belching is gas leaving through the mouth. The useful clinical question is what has changed: frequency, discomfort, visible size, bowel function or another symptom. Embarrassment should not prevent someone describing a problem that affects meals, work or sleep. NHS flatulence explanation.

Feeling swollen and becoming visibly larger can occur together or separately. Tell the clinician which you experience and whether it changes through the day. A symptom guide cannot establish a diagnosis from a photograph, the smell of wind or an assumed “normal” gas quota. Symptom distinction.

Why gas and bloating happen and when testing helps

Swallowed air and bacterial fermentation of incompletely digested carbohydrates contribute to gas. Gut sensitivity and movement also influence symptoms. Recognized disorders can overlap, including constipation, lactose intolerance, coeliac disease and IBS. It is important to identify the applicable explanation rather than attributing every symptom to one organism. Cause-based context.

The initial assessment may use history, examination and a food/symptom diary; testing is selected for a clinical question. Include medicines and supplements, recent changes and how bowel movements relate to discomfort. Ask what a proposed blood, stool or imaging test will clarify. NIDDK diagnostic approach.

Testing disagreements matter. The AGA discusses SIBO investigation in selected people at risk. The 2025 European functional-bloating consensus emphasizes poor performance of hydrogen-based SIBO breath testing. This does not invalidate every breath test for every purpose; ask about the precise indication and limitations. AGA selected-use context; European cautions.

Cause-specific bloating treatment and symptom relief

Treatment follows the cause: a person with constipation needs a different discussion from someone with confirmed lactose intolerance. NIDDK describes changing relevant air-swallowing habits and using condition-specific treatments. Avoid applying someone else’s prescription because both people use the word “bloating.” Cause-based treatment.

NHS information suggests a pharmacist can discuss simeticone or constipation treatment where appropriate. That is an option for symptom review, not proof that an over-the-counter product treats an undiagnosed cause. Check the complete formulation and explain new or persistent symptoms before repeatedly combining products. Pharmacist options.

For selected gut–brain disorders, clinicians may discuss psychological therapies, targeted breathing or biofeedback. Such care addresses real symptoms; choosing it does not establish that symptoms are imagined. Ask which mechanism or assessment finding the treatment is intended to address. Gut–brain care context.

A 2024 trial studied measured thoracoabdominal-motion biofeedback in a small selected group with meal-triggered visible distension. Its training and equipment should not be equated with a generic breathing video. Complete finance was not available, so this guide does not adopt its numerical efficacy claims. Original human trial.

Food triggers, low-FODMAP diets and probiotic evidence

A diary can help identify a reproducible food pattern. NIDDK describes possible carbohydrate and food-tolerance contributors; the aim is an individual explanation rather than avoiding every food that can ferment. Discuss whether an apparent trigger depends on amount, meal context or a diagnosed intolerance. Diet discussion.

In diagnosed IBS, NICE supports expert dietary help when general advice is insufficient, including a low-FODMAP approach where appropriate. It describes restriction followed by structured reintroduction and protecting adequate intake. Ask for the purpose and end point before turning a trial into a permanent exclusion list. Specialist dietary management.

Do not start a gluten-free diet before coeliac diagnostic testing without discussing it: restriction can change results. If gluten has already been removed, tell the clinician rather than inventing a self-directed challenge. Symptoms alone do not establish coeliac disease. Testing before restriction.

Probiotic advice differs. The AGA advises against using probiotics for bloating; the European consensus allows that selected strains may help but labels the evidence low certainty. Neither position establishes an independently verified universal product. Explain what you have tried and why you are considering another. AGA advice; European certainty limits.

Useful bloating outcomes, microbiome tests and formulation claims

Define a useful goal: less discomfort after meals, ability to eat adequately, less disruptive wind or easier bowel function. Ask whether the proposed treatment targets that outcome and how it will be reviewed. A change in a laboratory value should not automatically replace the symptom outcome that matters to you.

The European consensus advises against using microbiota analysis tests to evaluate functional bloating. A commercial “imbalance” score is not established here as a reason for antibiotics or a supplement bundle. Ask whether the test result has a validated clinical interpretation and changes appropriate care. Microbiota-test caution.

Formulation continuity also matters. A January 2026 correction clarifies that studies of the historical product sold as VSL#3 used the De Simone Formulation; the current product with that name is different. Old trial results cannot simply be transferred by brand name. No current brand is endorsed here. Original formulation correction.

Bloating warning signs and treatment risks

Seek emergency care for swollen abdomen with severe sudden pain, blood or coffee-ground-like vomit, or serious breathing difficulty. Inability to pass stool or wind, vomiting, fever or a new abdominal lump needs urgent assessment. Do not keep escalating home remedies while waiting for symptoms to settle. NHS emergency abdominal guidance; Bloating-specific urgent advice.

Regular or persistent bloating, blood in stool or unintentional weight loss warrants a clinical review. Persistent swelling can sometimes reflect serious causes, including ovarian disease; avoid assuming a long-standing label of IBS explains every new change. Tell the clinician how the current pattern differs. Persistent-symptom assessment.

Probiotic safety depends on the person and product. NCCIH highlights concerns in people with serious illness or compromised immune systems. A plausible microbiome mechanism does not establish either safety or benefit for that individual. Vulnerable-person safety.

Medicines, fibre products and supplement interactions

Medicines may contribute to wind or digestive symptoms. Take the full list to review, including non-prescription laxatives and products purchased online. Do not stop an essential treatment on the basis of bloating alone; ask whether an alternative or another explanation needs consideration. Medicine-related symptom context.

Bulk-forming fibre products have suitability limits, including suspected obstruction and swallowing difficulty. A new painful swollen abdomen is not a reason to take progressively more fibre without assessment. Ask about the actual preparation and any relevant instructions. Ispaghula precautions.

Mixed “digestive support” supplements may contain several ingredients. Bring the label so a pharmacist can review interactions and ingredient duplication. A familiar front-label term such as “natural” is insufficient information for that decision. Ingredient and interaction review.

Children, restrictive eating and complex conditions

Adult research cannot automatically establish what causes a child’s abdominal swelling. Explain growth, appetite, bowel changes and the timing of symptoms to the child’s clinician. Request an age-appropriate assessment and a clear explanation of which findings would change the plan.

Make nutritional difficulty visible before a diet trial. Discuss existing food restrictions, limited access to suitable meals, anxiety about eating or difficulty maintaining intake. A feasible plan needs to account for these circumstances rather than simply giving a longer avoidance list. Adequate intake and accessible dietary care.

If pregnancy, major illness, immune suppression or a fluid restriction affects treatment choices, tell the team before adding products. Ask how your circumstances change the proposed option and what symptoms should prompt contact. Do not copy the plan of a healthier adult studied in a trial.

Preparing a clinician-led bloating plan

Prepare a short account of when symptoms began, the main discomfort, visible swelling, stool changes and relevant treatments. Describe effects on meals, work and sleep. Bring prior test reports and the names of supplements, rather than just saying that a “gut panel” was abnormal.

Ask which explanation is most likely and which alternatives need evaluation. For a proposed test, ask what an abnormal or normal result would change. Clarify whether a treatment is addressing constipation, intolerance, sensitivity or another mechanism. You should be able to explain the purpose in ordinary language.

If a dietary or symptom-treatment trial is agreed, request a practical review point and a plan for reporting harms or worsening symptoms. Keep track of the outcome you agreed to assess. If several treatments are changed at once, discuss how the team will interpret improvement or new problems.

This guide gives no antibiotic course, probiotic dose, food-challenge quantity or biofeedback protocol. Ask the prescriber or trained clinician for the exact instructions applicable to the selected product or programme, and who to contact when the plan is difficult to follow.

Animal and laboratory microbiome research limits

Changes in fermentation, bacterial abundance or laboratory inflammatory markers cannot by themselves establish relief of human bloating. Useful research needs an appropriate diagnosis, comparison, symptom outcome, harms assessment and financial disclosure. No animal or in-vitro claim is used here to endorse a gut cleanse or supplement.

Funding and source roles

Public information explains symptoms and care; it does not clear every trial or outside expert. NIDDK’s acknowledged expert has historical commercial consulting disclosures, while AGA and European authors report commercial relationships. Unknown funding of the biofeedback trial remains unknown. Corporate efficacy is excluded from an independent verdict. The European correction is formulation context, not a product recommendation. Sources cover US/UK and European practice; local clinical pathways may differ.

Frequently asked questions

Is bloating the same as abdominal distension?

No. Bloating is a sensation; distension is an increase in abdominal size. They can occur together or separately.

Does bloating mean I have SIBO?

No. Symptoms overlap with several explanations, and test indications and limitations matter.

Do I need a stool microbiome test?

The European consensus does not support it for assessing functional bloating.

Should I stop gluten first?

Discuss coeliac testing before restriction because a gluten-free diet can affect results.

Which probiotic is best for bloating?

No independently verified universal winner is established here; guidelines disagree and formulation-specific evidence matters.

When is bloating an emergency?

Severe sudden pain, blood in vomit or serious breathing difficulty with swelling needs emergency care.

Is a low-FODMAP diet lifelong?

NICE dietary care includes an agreed restriction period followed by reintroduction and attention to adequate intake.

Can breathing exercises replace assessment?

No. Targeted trained treatment for a selected mechanism does not establish the cause of new symptoms.

Sources and funding notes

Primary journal disclosures, the original 2026 formulation correction, registry sponsor and current public symptom pages were checked. AGA original advice/disclosures and the correction were available through original indexed text after direct-access limits. The original biofeedback abstract/registry were accessible, but full preparation funding and author interests were not established; numerical efficacy is not used. The UEG report documents congress industry support, not the exact money behind its guideline grant. NHS simeticone medicine pages now redirect to an unavailable notice; no removed-page interaction or efficacy claim is adopted. Older public education and mixed-institution guidance are clinical context, not financial clearance of all research. Grades are provisional editorial credibility assessments, not guideline evidence grades.

1. NIDDK: gas symptoms causes — Gas generation, sensitivity, symptoms and overlapping disorders.
2. NIDDK: gas diagnosis — Symptom/food/medicine history, examination and selective tests.
3. NIDDK: gas treatment — Individual cause-based care, swallowed-air habits and condition-specific medicines.
4. NIDDK: gas eating diet nutrition — Food tolerance and selective dietary changes; no universal exclusion diet.
5. NHS: bloating, January 2026 — Current symptom, persistent-bloating and emergency advice.
6. NHS: flatulence — Normal variation, medicine-related symptoms and pharmacist review.
7. NIDDK: celiac-disease diagnosis — Gluten restriction before testing can alter results; diagnosis not symptoms alone.
8. NCCIH: probiotics — Strain/condition-specific uncertainty and vulnerable-person safety.
9. NIH ODS: supplement safety — Whole-ingredient and medicine-interaction review.
10. NHS: ispaghula suitability — Suspected obstruction and swallowing precautions.
11. NHS: stomach ache — Emergency abdominal pain, bleeding and obstruction warning signs.
12. NICE QS114: dietary management in IBS — Specialist-supported restriction and reintroduction in diagnosed IBS; not a diet prescription for every bloated person.
13. AGA clinical-practice update on bloating, 2023 — Selected SIBO assessment, gut–brain treatment context and recommendation against probiotics for bloating; not an independent efficacy verdict.
14. ESNM/UEG functional-bloating consensus, 2025 — Bloating mechanisms, microbiota-test and breath-test cautions; low-certainty strain-specific probiotic disagreement.
15. Original January 2026 correction to the European consensus — Historical VSL#3 trial formulation differs from the current product with that name; no brand endorsed.
16. Thoracoabdominal-motion biofeedback trial, 2024 — Measured, trained biofeedback studied in selected visible distension; no home protocol or numerical benefit adopted.
17. NCT04043208: original trial registry — Trial-sponsor provenance only; no comparative clinical benefit inferred.
18. Lacy et al. 2021 primary clinical review: conflict disclosure — Outside-expert conflict provenance; review efficacy estimates not adopted.

Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.